James Healy just made a big buy of their own company's stock.

1. The buy: Director at Rapport Therapeutics, Inc., 969,480 shares of RAPP on 28 October 2026 -- $20,359,080 at $21.00 a share.
2. The entry: that price is real, not an estimate -- a Form 4 discloses the price actually paid, so this is their fill. It is what they paid on their own trade date, though, not a price available now.
3. Filed: 30 October 2026.

Risk: one person buying a lot is the whole signal here. Grants, option exercises, tax withholdings and scheduled 10b5-1 plan purchases are excluded, since none of them is somebody choosing to put money in today; so are purchases by holders who are neither officers nor directors, which are funds building a position rather than a person making a decision. An automated tracker of public SEC filings, not a recommendation.